eli_lilly_logo

Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance

pharmafile | May 26, 2016 | News story | Research and Development, Sales and Marketing Cancer Drugs Fund, Eli Lilly, NICE, lung cancer 

The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat lung cancer saying the therapy cost too much compared to combination chemotherapy. 

The appraisal committee also concluded that necitumumab did not meet the criteria to be considered for use in the Cancer Drugs Fund as it was not cost-effective and no clinical uncertainties could be addressed from further data collection. 

The regulator in a draft guidance however, acknowledged that necitumumab provides small improvements in overall survival. 

Advertisement

Anjali Shukla

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

HUTCHMED completes enrolment in phase 3 trial for lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

The Gateway to Local Adoption Series

Latest content